Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Dong-Yuan Chang1,2,3†, Xiao-Qian Li1,2,3†, Min Chen1,2,3* and Ming-Hui Zhao1,2,3

1Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China, 2Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China, 3Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China

Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms. Over-activation of the complement system, a crucial part of innate immunity, plays an important role in DKD. We aimed to investigate the effect of SGLT2 inhibitors on alleviating complement over-activation in DKD. Db/db mice were randomly divided into two groups, with 7 mice in each group treated with dapagliflozin and vehicle respectively, and 7 mice in m/m mice group. Laboratory and renal pathological parameters were evaluated. Mouse proximal tubular epithelial cells (MPTECs) were cultured and treated with high glucose. Dapagliflozin and dimethyloxallyl glycine (DMOG) were added as conditional treatment. Dapagliflozin-treated db/db mice showed significantly lower urinary albumin than vehicle-treated ones. Besides typical glomerular and tubulointerstitial injury, both C3b and membrane attack complex (MAC) depositions were significantly attenuated in dapagliflozin-treated db/db mice. The expression of complement receptor type 1-related protein y (Crry), a key complement regulator which inhibits complement over-activation, was significantly upregulated by dapagliflozin. Dapagliflozin-mediated Crry upregulation was associated with inhibition of HIF-1α accumulation under high glucose. When HIF-1α expression was stabilized by DMOG, the protective effect of dapagliflozin via upregulating Crry was blocked. In conclusion, dapagliflozin could attenuate complement over-activation in diabetic mice via upregulating Crry, which is associated with the suppression of HIF-1α accumulation in MPTECs.

Keywords: sodium glucose co-transport-2 (SGLT2) inhibitors, dapagliflozin, diabetic kidney disease, complement over-activation, complement receptor type 1-related protein y (Crry), hypoxia inducible factor-1α (HIF-1 α)

INTRODUCTION

With the increasing prevalence of diabetes, diabetic kidney disease (DKD) has surpassed glomerulonephritis and become the leading cause of chronic kidney disease and end-stage renal disease (ESRD) (Zhang et al., 2016; Wang et al., 2017; Ma, 2018). However, the effective prevention and treatment of DKD were still limited. The sodium-glucose cotransporter 2 (SGLT2) inhibitor is a novel anti-diabetic medication, targeting renal proximal tubules to reduce glucose reabsorption, resulting in increased urinary...
glucose excretion and anti-hyperglycemic effects (Uthman et al., 2018; Wilcox et al., 2018). A number of recent clinical trials demonstrated prominent renal protective effects of SGLT2 inhibitors (Wanner et al., 2016; Neal et al., 2017; Wiviott et al., 2019). SGLT2 inhibitors have already been recommended as the first-line medication for patients with chronic kidney diseases for the management of type 2 diabetes (Kidney Disease: Improving Global Outcomes Diabetes Work, 2020). However, the renal protective mechanism of SGLT2 inhibitors has not been fully clarified. Cumulating evidence suggests that, besides the anti-hyperglycemic effect, SGLT2 inhibitors have a remarkable anti-inflammatory role in DKD (Ashrafii Jigh et al., 2019; Hasan et al., 2020; Pirklbauer et al., 2020).

Immune inflammation, especially innate immunity, plays an important role in the pathogenesis of DKD (Tesch, 2017; Tang and Yiu, 2020). The complement system is an important part of innate immunity, with functions of cleaving pathogens, clearing immune complexes and participating in inflammatory response (Kolev et al., 2014). The complement system can be activated through three pathways including classical, lectin and alternative pathway. Complement regulatory proteins, mainly including human membrane cofactor protein (MCP, CD46), decay accelerating factor (DAF, CD55) and CD59, inhibit the key steps of complement cascade activation, thus protect tissue cells from damage by complement over-activation. Complement receptor type 1-related protein y (Crry) is a key complement regulatory protein of mice with similar function to CD46 and CD55 in human (Nangaku, 1998; Thurman et al., 2006; Miwa et al., 2007). There is growing evidence that over-activation of the complement system plays an important role in the development of DKD (Li et al., 2019a; Li et al., 2019b; Huang et al., 2019; Sun et al., 2019), including two aspects of mechanism. One is that advanced glycation of proteins generates neo-epitopes to which lectin pathway pattern recognition molecules bind. Meanwhile, glycation-induced dysfunction or inactivation of complement regulatory proteins is another important mechanism for the complement over-activation in DKD (Qin et al., 2004; Ostergaard et al., 2007).

On the other hand, in early and advanced stages of DKD, hypoxia in renal proximal tubules is a common feature (Friederich-Persson et al., 2013; Liu et al., 2017). Hypoxia-inducible factor (HIF)-1α is a key molecule playing an adaptive reaction in hypoxic conditions. The diabetic kidney is characterized by abnormalities in HIF-1α signaling. Accumulated HIF-1α was associated with renal tissue damage including inflammation and fibrosis (Baumann et al., 2016; Nayak et al., 2016; McGlackin and O’Neill, 2020). Recent studies suggested HIF-1α could be a therapeutic target of SGLT2 inhibitors in DKD, and multiple molecular mechanisms were investigated but still unclear (Bessho et al., 2019; Cai et al., 2020; Li et al., 2020). Pandya et al. (2016) found that there was potential association between HIF-1α and CD55 in respiratory epithelium. Therefore, whether there is similar regulatory relationship in kidneys is of interest.

In the present study, we hypothesized that the SGLT2 inhibitor could alleviate complement over-activation in DKD via upregulating Crry, which was associated with the suppression of HIF-1α accumulation.

**MATERIALS AND METHODS**

**Animal Experimentation**

Male db/db (Lepr db/db) and m/m mice (C57BL/KsJ mice) were obtained from Nanjing Biomedical Research Institute of Nanjing University. The mice were housed in the Animal Center of Peking University First Hospital with a 12-h light/dark cycle allowing free access to food and water when they were 3 weeks old. After 1 week (at the age of 4 weeks), db/db mice were randomly divided into two groups, with 7 mice for each group. For dapaglirozin-treated group, the dosage of dapaglirozin (AstraZeneca Pharmaceuticals LP) was 1 mg/kg/day and the solvent was 0.5% methylcellulose. The control groups received solvent as vehicle without active pharmacological effect.

24-h urine was collected to measure urinary albumin at the 8th and 14th week. Mice were placed in a 24-h metabolic cage for urine collection. Urinary albumin levels were measured by a mouse albumin ELISA kit (Bethyl Laboratories, Montgomery, TX, United States). Urinary creatinine levels were assayed by a Creatinine Assay Kit (DICT-500; BioAssay Systems, CA, United States). The mice were sacrificed at the age of 14 weeks. No adverse effect was found in dapaglirozin-treated db/db mice. All animal experiments were approved by the Laboratory Animal Ethics Committee of Peking University First Hospital (No. 202039).

**Morphological Analysis and Immunohistochemistry**

Formalin-fixed paraffin-embedded kidney tissue sections were stained with periodic acid-Schiff (PAS, BA-4080B; BASO, Zhuhai, China) solution. The glomerular injury was evaluated by mesangial matrix fraction. The percentage of mesangial matrix expansion area to the glomerular tuft area was calculated in at least 20 glomeruli per renal section randomly selected and digitized under ×400 magnification (Yiu et al., 2016). Image-Pro Plus software V.6.0 (Media Cybernetics, Bethesda, MD) was used to analyze. Tubulointerstitial injury was scored from 0 to 5 according to the percentage of damaged tubulointerstitium (tubular dilation, vacuolar degeneration, interstitial inflammation and cast formation): 0, normal; 1, lesion <10%; 2, 10–20% lesion; 3, 20–30% lesion; 4, 30–40% lesion; 5, >40% lesion (Yiu et al., 2016). For immunostaining of C3b and membrane attack complex (MAC), renal tissues were treated with 3% H2O2, blocked by 3% bovine serum albumin, and stained with anti-C3b antibody (sc-133172; Santa Cruz, CA, United States) and anti-MAC antibody (553,043; BD Pharmingen, NJ, United States) overnight at 4°C, respectively. Then the secondary antibody (PV-9002, PV-9004; ZSBIO, Beijing, China) was used, followed by color development using 3, 3′-diaminobenzidine (ZLI-9018; ZSBIO). The integrated optical density (IOD) was used to represent the deposition of
C3 and MAC in kidneys. The images were analyzed by Image-Pro Plus under×200 magnification.

Transmission Electron Microscopy
The renal cortical tissues of mice were cut into three 1 mm³ cubes and immediately immersed into 3% glutaraldehyde after sacrifice. Further sample handling was performed by the Laboratory of Electron Microscopy, Peking University First Hospital. Two glomeruli were randomly selected from each renal sample and a total of 15–20 representative non-overlapping digital micrographs from each glomerulus were taken on an electron microscope (Hitachi 7700 transmission, Tokyo) under×10,000 magnification. The number of foot process per micrometer of glomerular basement membrane (GBM) was calculated using Photoshop or ImageJ.

Cell Culture
The primary renal proximal tubular cells were extracted from male C57BL/6J mice (3 weeks old) (Kamiyama et al., 2012). Cells were seeded in 6 or 12-well plates as needed and cultured in Epithelial Cell medium (EpiCM-A; ScienCell, United States) supplemented with 2% fetal bovine serum (FBS; ScienCell), 1% penicillin-streptomycin (ScienCell) and 1% EpiCGS-a (ScienCell) in 37°C in an incubator containing 5% CO2 and 95% humidified air. When reaching approximately 70% confluence, the medium was replaced, and the cells were exposed to different stimuli with penicillin-streptomycin (ScienCell) and 1% EpiCGS-a (ScienCell) medium. The primary renal proximal tubular cells were screened for 24 h, including 30 mmol/L d-glucose (HG) (G8270, Sigma Aldrich), D-mannitol (MAN) (M4125, Sigma Aldrich) and dimethylxallyl glycine (DMOG) (3695; Sigma-Aldrich, St Louis, United States).

Western Blot Analysis
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate denatured proteins. Total proteins were transferred electrophoretically to polyvinylidene difluoride transfer membranes (PVDF, Millipore, Bedford, MA, United States). The membrane was incubated with the primary antibody (HIF-1α 10006421; Cayman, United States, dilution 1:200), and then was incubated with a peroxidase-conjugated secondary antibody. Proteins were visualized on an autoradiographic film using an ECL Plus Western blot detection system (GE Healthcare).

Quantitative Real-Time Polymerase Chain Reaction Analysis
Total RNA of renal cortical tissues or cultured cells was extracted using RNAprep pure Kit (Tiangen, China) and reverse transcribed into cDNA with High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, MA, United States). The qRT-PCR analysis was carried out in an ABI Prism 7500 sequence detection system (Applied Biosystems) using SYBR green Master Mix (Applied Biosystems). Relative gene expression was normalized to 18s rRNA. Data were presented as a relative fold change compared with the control group. Primers used for mRNA detection are listed in Supplementary Table S1.

Flow Cytometry Assay
Indirect labelling flow cytometry assay was used to measure Crry expression with a primary antibody (550058; BD Pharmingen), and then with a compatible secondary antibody (405407; APC Goat anti-rat IgG, Biolegend).

Terminal-Deoxynucleotidyl Transferase Mediated Nick End Labeling Assay
Terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL) assay was performed using In Situ Cell Death Kit (Roche Diagnostics, Mannheim, Germany) to detect apoptotic cells according to the manufacturer’s instructions. Cells were incubated with 4% paraformaldehyde (PFA) for 20 min and permeabilized with 0.1% Triton X-100 for 15 min. Then, the specimens were incubated for 1 h in working strength TdT enzyme solution at 37°C. The slides were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI).

Statistical Analysis
The data were expressed as the means ± standard deviation. Parametric data were analyzed with one-way Anova (Tukey test). Non-parametric analyses of histological scores were conducted using a Spearman’s test with the unpaired, non-parametric Mann-Whitney U test as appropriate. p values < 0.05 were considered statistically significant. GraphPad prism 5.0 was used for statistical analysis.

RESULTS
Dapagliflozin Ameliorated Diabetic Kidney Disease in db/db Mice
To confirm the effect of dapagliflozin in vivo, we treated type 2 diabetic db/db mice with dapagliflozin for 10 weeks. Compared with m/m mice, both vehicle-treated db/db mice and dapagliflozin-treated db/db mice had significantly higher body weight, kidney weight/body weight ratio, fasting blood glucose, urinary albumin/creatinine ratio (UACR) and 24-h urinary albumin excretion. Dapagliflozin-treated db/db mice showed significantly lower levels of fasting blood glucose and urinary albumin excretion compared with vehicle-treated db/db mice (21.83 ± 6.05 vs. 15.46 ± 4.03 mmol/L, p = 0.044; 307.69 ± 98.34 vs. 174.72 ± 70.75 mg/24h, p = 0.011, respectively) (Table 1). Marginally significant decreasing of UACR was observed in dapagliflozin-treated db/db mice compared with vehicle-treated db/db mice (385.53 ± 178.27 mg/g Cr vs. 230.40 ± 72.48 mg/g Cr, p = 0.054). No adverse event was found in any experimental group.

In PAS staining, notably increased mesangial matrix expansion and tubulointerstitial injury were detected in db/db mice compared with m/m controls (p < 0.001 and p < 0.001, respectively, Figures 1A,C,E). The ratio of mesangial matrix expansion area to the glomerular tuft area and tubulointerstitial injury were significantly attenuated in dapagliflozin-treated db/db mice compared with vehicle-treated db/db mice (p = 0.003, p < 0.001, respectively, Figures 1A,C,E).
TABLE 1 | Laboratory data of mice.

|                      | m/m mice      | Vehicle treated db/db mice | SGLT2i treated db/db mice |
|----------------------|---------------|----------------------------|---------------------------|
| body weight, g       | 25.4 ± 1.77   | 49.96 ± 4.56**             | 55.38 ± 5.76              |
| kidney weight/body weight | 0.0058       | 0.0044*                    | 0.0040                    |
| water intake, ml/24h | 5.60 ± 1.08   | 24.35 ± 8.74**             | 20.43 ± 9.75              |
| food intake, g/24h   | 4.48 ± 0.48   | 14.16 ± 1.42**             | 14.11 ± 1.88              |
| urine volume, ml/24h | 0.83 ± 0.18   | 17.07 ± 7.01**             | 16.29 ± 5.24              |
| fasting blood glucose, mmol/L | 7.90 ± 1.28 | 21.83 ± 6.05**             | 15.46 ± 4.03†             |
| UACR, ug/mg          | 75.34 ± 22.74 | 385.53 ± 178.27**          | 230.40 ± 72.48            |
| urine total albumin, mg/24h | 20.96 ± 5.07 | 307.69 ± 98.34**          | 174.72 ± 70.75†          |

Metabolic parameters and urine test of m/m, db/db mice and Dapagliflozin-treated db/db mice. Four-week-old db/db mice (n = 7) were treated with 1 mg/kg/day Dapagliflozin for 10 weeks. Values are means ± SD. UACR: urinary albumin creatinine ratio; m/m mice:C57BL/6J mice.

* p < 0.05, ** p < 0.01 compared with m/m mice (n = 5).
† p < 0.05 compared with vehicle-treated db/db mice (n = 7).

FIGURE 1 | Dapagliflozin ameliorated diabetic kidney disease in db/db mice. (A) Representative PAS staining of kidney biopsy from m/m mice (n = 5), vehicle-treated db/db mice (n = 7) and SGLT2-i-treated db/db mice (n = 7) showing mesangial matrix expansion, Bar = 100 μm. (B) Representative ultrastructure changes of GBM by electron microscopy under ×10000 magnification, n = 3 for each group. (C) Semiquantitative analysis of mesangial matrix expansion. (D) The number of foot processes. (E) Semiquantitative analysis of tubulointerstitial injury. PAS, periodic acid-Schiff; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GBM, glomerular basement membrane; MPTEC, mouse proximal tubular epithelial cell; DMOG, dimethylxoyl glycine.
FIGURE 2 | Dapagliflozin suppressed kidney complement over-activating in db/db mice and upregulated Crry expression. (A) Representative immunohistochemical staining of C3b from m/m mice (n = 5), vehicle-treated db/db mice (n = 7) and SGLT2i-treated db/db mice (n = 7), Bar = 100 μm. (B) Representative immunohistochemical staining of MAC. (C) Integral optical density of C3b deposition. (D) Integral optical density of MAC deposition. Real-time qPCR analysis of mRNA level change (E) MBL, (F) C2, (G) CD55, (H) Crry, (I) CD59. MBL, mannan binding lectin; C2, complement 2; MAC, membrane attack complex.
By electron microscopy, dapagliflozin-treated db/db mice showed significant improvement in thickening of GBM compared with vehicle-treated db/db mice ($p = 0.005$, Figures 1B,D).

Collectively, dapagliflozin ameliorated diabetic kidney disease in db/db mice including laboratory and pathological indexes.

**Dapagliflozin Upregulated Crry Expression and Suppressed Kidney Complement Over-Activating in db/db Mice**

Then we investigated the effect of dapagliflozin on the complement system in diabetic mice. Both C3b and MAC deposition were significantly reduced in dapagliflozin-treated db/db mice compared with vehicle-treated db/db mice ($p = 0.008$ and $p = 0.009$, respectively, Figures 2E,F).

Compared with vehicle-treated db/db mice, the mRNA levels of complement regulatory proteins including CD55, Crry and CD59 were significantly upregulated in dapagliflozin-treated db/db mice ($p = 0.038$, $p = 0.042$ and $p = 0.047$, respectively, Figures 2G–I).

**Dapagliflozin Relieved Tubular Cell Injury by Upregulating Crry and Inhibiting High Glucose-Induced HIF-1α Protein Accumulation in vitro**

As mentioned above, Crry is a key complement regulator in rodents, with similar function to MCP and CD55 in human. Li et al., 2018.
et al., 2019b; Qin et al., 2004; Ostergaard et al., 2007). In order to further demonstrate whether dapagliflozin can upregulate Crry protein expression, we utilized the mouse primary tubular epithelial cells (MPTECs). Under high glucose condition (30 mmol/L), the expression of Crry in MPTECs was significantly reduced ($p = 0.012$, compared with D-mannitol-treated MPTECs, Figure 3A). The reduced Crry was upregulated by dapagliflozin (dapagliflozin 100 μmol/L, this dose was selected according to previous studies) (Bessho et al., 2019; Cai et al., 2020; Li et al., 2020) under HG condition ($p = 0.031$, compared with vehicle-treated MPTECs, Figure 3A). In line with the increasing of Crry, key markers of inflammation including TNF-α, IL-1α, CD68 and IL-18 under HG condition were reduced in mRNA level in MPTECs treated with dapagliflozin, as compared with vehicle-treated MPTECs (Figures 3E–H). Moreover, under high glucose condition, the TUNEL assay revealed significantly lower level of apoptosis in dapagliflozin-treated MPTECs compared with the vehicle-treated MPTECs ($p = 0.034$, Figures 3C,D).

Furthermore, we investigated whether HIF-1α accumulation under high glucose condition was relieved by dapagliflozin, and whether dapagliflozin upregulated Crry expression via decreasing HIF-1α. HIF-1α accumulation was stabilized in MPTECs by DMOG (1 mmol/L), a prolyl hydroxylase (PHD) inhibitor. When MPTECs were treated with DMOG based on high glucose and dapagliflozin, Crry expression was remarkably reduced with the stabilization of HIF-1α accumulation ($p = 0.025$ and $p = 0.041$, respectively, compared with high glucose and dapagliflozin-treated MPTECs without DMOG, Figures 3B,3,I,J), indicating the effect of dapagliflozin on upregulating Crry expression was reduced by HIF-1α stabilizer. With the reducing of Crry, the above markers of inflammation and apoptosis significantly increased (Figures 3E,F,H).

Collectively, dapagliflozin restored Crry protein expression via reducing HIF-1α accumulation in MPTECs.

**DISCUSSION**

The current study found that the SGLT2 inhibitor alleviates complement over-activation by upregulating Crry expression via reducing HIF-1α accumulation in renal proximal tubular cells in DKD.

Increasing evidence demonstrated that the inflammatory process mediated mainly by innate immunity is among the central pathophysiology of DKD (Tang and Yiu, 2020). As a key part of innate immunity, the complement system is actively involved in the pathogenesis of DKD (Tang and Yiu, 2020; Kolev et al., 2014; Nangaku, 1998). Our previous studies also showed that complements were over-activated in DKD (Li et al., 2019a; Li et al., 2019b; Sun et al., 2019). Inhibiting complement over-activation is a potential therapeutic strategy for DKD.

In the current study, we found that dapagliflozin treatment significantly reduced C3b and MAC deposition in kidney tissues of db/db mice. Further investigation suggested that such alleviation of complement over-activation by dapagliflozin was associated with the upregulating of Crry. The murine cell surface protein Crry is a key complement regulator with similar function to MCP and CD55 in human. Previous studies found that Crry is critical for regulating complement activation within kidney tubules (Nangaku, 2006; Thurman et al., 2006). During ischemia-reperfusion challenge, Crry also has a critical role in protecting proximal tubular epithelial cells (Thurman et al., 2006). We speculated that in human DKD, dapagliflozin might improve DKD by, at least in part, upregulating MCP or CD55, and thus relieves complement over-activation.

Tubular injury is an important aspect of DKD, and tubular hypoxia is the main driving force for proximal tubulopathy (Mimura and Nangaku, 2010). Hyperglycemia induces glomerular hyperfiltration and increases tubular reabsorption of sodium and glucose through SGLTs, which enhance the activity of sodium-potassium-ATPase, resulting in increased oxygen and energy consumption. Thus, proximal tubular cells in diabetic kidneys are exposed to chronic hypoxia. For rodent models, previous studies demonstrated that SGLT2 inhibitors ameliorated hypoxia in the kidney cortex (Hayton et al., 2016; O’Neill et al., 2015). HIF-1α was proposed as a therapeutic target of the SGLT2 inhibitor for DKD (Bessho et al., 2019; Cai et al., 2020; Li et al., 2020). In this study, we found that dapagliflozin decreased HIF-1α expression, leading to upregulation of Crry. HIF-1α is an important transcription factor of mammalian oxygen sensing. Under hypoxia condition, HIF-1α can maintain stable and bind with HIF-1β, then activate and increase gene transcription (O’Neill et al., 2015; Majmundar et al., 2010; Kaelin and Ratcliffe, 2008). It can regulate glucose metabolism, cell proliferation, angiogenesis proteins and inflammation (Dengler et al., 2014). As a key part of innate immunity, complement over-activation plays an important role in the pathogenesis of DKD. A previous study showed an important role for HIF-1α in regulating CD55 expression on airway epithelium in vitro and in vivo (Pandya et al., 2016), which prompts us to investigate whether dapagliflozin upregulates Crry via relieving HIF-1α accumulation in the kidney.

To our knowledge, this is the first study investigating the relationship between HIF-1α and complement regulators in kidneys. The exact molecular mechanism of HIF-1α regulating complement regulator expression is not fully clear. One speculation is that transcriptional downregulation may occur through epigenetic modifications. Hypoxia targets Jumonji AT-rich interactive domain 1A (JARID1A) activity, which in turn increases Histone H3 lysine 4 (H3K4) trimethylation (H3K4me3), leading to the altered programs of gene expression including CD55 (Zhou et al., 2010; Kiernan et al., 2020). The current study found that dapagliflozin reduced HIF-1α accumulation, upregulated Crry and ameliorated complement over-activation; with the accumulation of HIF-1α stabilized by DMOG, the expression of Crry was decreased. The upregulation of Crry expression by dapagliflozin might improve DKD, at least in part, via strengthening the key protective defense on complement over-activation which was added to the hypoglycemic effect. It should be note that no obvious change for Crry mRNA between m/m and db/db mice was observed in the current study, indicating that there is little, if any, pathological relevance associated with Crry in kidneys of db/db mice. Therefore, the effect of dapagliflozin on upregulating Crry expression might be achieved through the pharmacological way rather than the physiological way.
There are several limitations of our study. First, isoforms of HIFs other than HIF-1α exist, such as HIF-2α and HIF-3α. We focused on HIF-1α in our studies due to its ubiquitous expression and its strong induction during hypoxia. However, the current study does not exclude the possibility of other HIF isoforms in regulating Crry. Second, the effect of dapagliflozin on other intrinsic cells of kidneys including mesangial cells and podocytes was not clarified. Third, the numbers of animals included is limited, studies with larger sample size are needed.

In conclusion, this study provides a novel mechanism of the protective role of SGLT2 inhibitors in DKD. Clarifying the molecular regulatory mechanisms of complement regulators and HIF-1α expression by SGLT2 inhibitors will lead to improvement to manage DKD (Singh et al., 2020).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Laboratory Animal Ethics Committee of Peking University First Hospital (No. 202039).

REFERENCES

Ashrafi Jigheh, Z., Ghorbani Haghjo, A., Argami, H., Roshangar, L., Rashtchizadeh, N., Sanajoo, D., et al. (2019). Empagliflozin Alleviates Renal Inflammation and Oxidative Stress in Streptozotoxin-Induced Diabetic Rats Partly by Repressing HMGB1-TLR4 Receptor axis. Iran J. Basic Med. Sci. 22 (4), 384–390. doi:10.22038/ijbms.2019.31788.7651

Baumann, B., Hayashida, T., Liang, X., and Schnaper, H. W. (2016). Hypoxia-inducible Factor-1α Promotes Glomerulosclerosis and Regulates COL1A2 Expression through Interactions with Smad3. Kidney Int. 90 (4), 797–808. doi:10.1016/j.kint.2016.05.026

Bessho, R., Takiyama, Y., Takiyama, T., and Kitsunai, H. (2019). Hypoxia-inducible Factor-1α Is the Therapeutic Target of the SGLT2 Inhibitor for Diabetic Nephropathy. Sci. Rep. 9 (1), 14754. doi:10.1038/s41598-019-51343-1

Cai, T., Ke, Q., Fang, Y., Wen, P., Chen, H., Yuan, Q., et al. (2020). Sodium-glucose Cotransporter 2 Inhibition Suppresses HIF-1α-Induced Metabolic Switch from Lipid Oxidation to Glycolysis in Kidney Tubule Cells of Diabetic Mice. Cell Death Dis 11 (5), 390. doi:10.1038/s41419-020-25444-7

Dengler, V. L., Galbraith, M., and Espinosa, J. M. (2014). Transcriptional Regulation by Hypoxia Inducible Factors. Crit. Rev. Biochem. Mol. Biol. 49 (1), 1–15. doi:10.3109/10409233.2015.1538205

Friedrich-Persson, M., Thörn, E., Hansell, P., Nangaku, M., Levin, M., and Palm, F. (2013). Kidney Hypoxia, Attributable to Increased Oxygen Consumption, Induces Nephropathy Independently of Hyperglycemia and Oxidative Stress. Hypertension 62 (5), 914–919. doi:10.1161/HYPERTENSIONAHA.113.01425

Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Parvez, F., et al. (2020). Canagliflozin Ameliorates Renal Oxidative Stress and Inflammation by Stimulating AMPK-Akt-eNOS Pathway in the Isoprorenaline-Induced Oxidative Stress Model. Sci. Rep. 10 (1), 14659. doi:10.1038/s41598-020-71599-2

Huang, Y., Xu, J., Wu, X., Chen, X., Bai, X., Zhuang, Y., et al. (2019). High Expression of Complement Components in the Kidneys of Type 2 Diabetic Rats with Diabetic Nephropathy. Front. Endocrinol. (Lausanne) 10, 459. doi:10.3389/fendo.2019.00459

Kaelin, W. G., Jr., and Ratcliffe, P. J. (2008). Oxygen Sensing by Metazoans: the central Role of the HIF Hydroxylase Pathway. Mol. Cell 30 (4), 393–402. doi:10.1016/j.molcel.2008.04.009

Kamiyama, M., Garner, M. K., Farragut, K. M., and Kobori, H. (2012). The Establishment of a Primary Culture System of Proximal Tubule Segments Using Specific Markers from normal Mouse Kidneys. Int. J. Mol. Sci. 13 (4), 5098–5111. doi:10.3390/ijms13045098

Kidney Disease: Improving Global Outcomes Diabetes Work, G. (2020). KDIGO 2019 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 98 (4S), S1–S115. doi:10.1016/j.kint.2020.06.019

Kiernan, E. A., Ewald, A. C., Ouellette, J. N., Wang, T., Agbeh, A., Knutson, O. A., et al. (2020). Prior Hypoxia Exposure Enhances Murine Microglial Inflammatory Gene Expression In Vivo without Comitant H3K4me3 Enrichment. Front Cell Neurosci 14, 535549. doi:10.3389/fncel.2020.535549

Kolye, M., Le Fric, G., and Kempner, C. (2014). Complement?tapping into New Sites and Effector Systems. Nat. Rev. Immunol. 14 (12), 811–820. doi:10.1038/nri3761

Layton, A. T., Vallon, V., and Edwards, A. (2016). Predicted Consequences of Diabetes and SGLT Inhibition on Transport and Oxygen Consumption along a Rat Nephron. Am. J. Physiol. Ren. Physiol 310 (11), F1269–F1283. doi:10.1152/ajprenal.00543.2015

Li, J., Liu, H., Takagi, S., Kitada, M., Srivastava, S. P., Takagaki, Y., et al. (2020). Renal Protective Effects of Empagliflozin via Inhibition of EMT and aberrant Glycolysis in Proximal Tubules. ICI Insight 5 (6). doi:10.1107/ICI-Insight.129034

Li, X. Q., Chang, D. Y., Chen, M., and Zhao, M. H. (2019). Complement Activation in Patients with Diabetic Nephropathy. Diabetes Metab. 45 (3), 248–253. doi:10.1016/j.diabet.2018.04.001

Li, X. Q., Chang, D. Y., Chen, M., and Zhao, M. H. (2019). Deficiency of C3a Receptor Attenuates the Development of Diabetic Nephropathy. BMJ Open Diabetes Res. Care 7 (1), e000817. doi:10.1136/bmjdrce-2019-000817

Liu, Z. Z., Bullen, A., Li, Y., and Singh, P. (2017). Renal Oxygenation in the Pathophysiology of Chronic Kidney Disease. Front. Physiol. 8, 385. doi:10.3389/fphys.2017.00385

AUTHOR CONTRIBUTIONS

D-YC and X-QL contributed to study design, literature search, data extraction, risk of bias assessment, data collection, interpretation of data and drafting of the manuscript, and gave final approval of the manuscript. MC and M-HZ contributed to study design, interpretation of data and revising of the manuscript, and gave final approval of the manuscript. MC is guarantor of this study.

FUNDING

This study is supported by a grant from China International Medical Foundation—Renal Anemia Fund, the grants from the National Natural Science Fund (Nos. 82070748, 82090020 and 82090021) and CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046). The funders had no role in study design, data collection and analysis, decision to publish or writing of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.729334/full#supplementary-material
Ma, R. C. W. (2018). Epidemiology of Diabetes and Diabetic Complications in China. Diabetologica 61 (6), 1249–1260. doi:10.1007/s00125-018-4557-7

Majmundar, A. J., Wong, W. J., and Simon, M. C. (2010). Hypoxia-inducible Factors and the Response to Hypoxic Stress. Mol. Cell 40 (2), 294–309. doi:10.1016/j.molcel.2010.09.022

McGettrick, A. F., and O’Neill, L. A. J. (2020). The Role of HIF in Immunity and Inflammation. Cell Metab 32 (4), 524–536. doi:10.1016/j.cmet.2020.08.002

Mimura, I., and Nangaku, M. (2010). The Suffocating Kidney: Tubulointerstitial Hypoxia in End-Stage Renal Disease. Nat. Rev. Nephrol. 6 (11), 667–678. doi:10.1038/nrneph.2010.124

Miwa, T., Zhou, L., Tudoran, R., Lambris, J. D., Madaio, M. P., Nangaku, M., et al. (2007). CAF/Cry Double Deficiency in Mice Exacerbates Nephrotic Proteinuria Despite Markedly Reduced Systemic Complement Activity. Mol. Immunol. 44 (1-3), 139–146. doi:10.1016/j.molimm.2006.06.023

Nangaku, M. (2006). A Crry for Polar Shedding. J. Pathol. 207 (5), 563–566. doi:10.1002/path.1816

Nangaku, M. (1998). Complement Regulatory Proteins in Glomerular Diseases. Mol. Immunol. 35 (1-2), 1–11. doi:10.1016/S0161-5850(97)00025-8

Pirklbauer, M., Bernd, M., Fuchs, L., Staudinger, P., Corazza, U., Leierer, J., et al. (2018). Class Effects of SGLT2 Inhibitors in Mouse Cardiomyocytes and Hearts: Inhibition of Na(+)/H(+) Exchanger, Lowering of Cytosolic Na(+), and Vasodilation. Diabetologia 61 (3), 722–726. doi:10.1007/s00125-017-4509-7

Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., et al. (2017). Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA 317 (24), 2515–2523. doi:10.1001/jama.2017.7596

Wanner, C., Inzucchi, S. E., and Lachin, J. M., (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 375 (4), 323–334. doi:10.1056/NEJMoa1515920

Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., and Grifffen, S. C. (2018). Interaction between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J. Am. Heart Assoc. 7 (4). doi:10.1161/JAHA.117.007046

Wiviott, S. D., Raz, I., and Bonaca, M. P., (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 380 (4), 347–357. doi:10.1056/NEJMoa1812839

Yiu, W. H., Wong, D. W., Wu, H. J., Li, R. X., Yam, I., Chan, L. Y. Y., et al. (2016). Kallistatin Protects against Diabetic Nephropathy in Db/db Mice by Suppressing AGE-RAGE-Induced Oxidative Stress. Kidney Int. 89 (2), 386–398. doi:10.1016/j.kint.2015.331

Zhang, L., Long, J., and Jiang, W. (2016). Trends in Chronic Kidney Disease in China. N. Engl. J. Med. 375 (9), 903–906. doi:10.1056/NEJMct1602469

Zhou, X., Sun, H., Chen, H., Zavadil, J., Klus, D., Artia, A., et al. (2010). Hypoxia Induces Trimethylated H3 Lysine 4 by Inhibition of JARID1A Demethylase. Cancer Res. 70 (10), 4214–4221. doi:10.1158/0008-5472.CAN-09-2942

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chang, Li, Chen and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.